Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Jul 7, 2019

Keywords

ClinConnect Summary

In this study, type 2 diabetes patients were treated with three kinds of SGLT2 inhibitors (dapagliflozin, empagliflozin and canagliflozin) for one week. With routine dose applied, (dapagliflozin 10mg/d, empagliflozin 10mg/d, canagliflozin 100mg/d), blood glucose level could be improved with small expected effect on body weight and no effect in lipid metabolism after the treatment period of one week. Normal glucose tolerance subjects (diagnosed of OGTT) were included as the control group.According to previous studies in three major SGLT2 inhibitors currently on the market, an increase in uri...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1)According to the diagnostic criteria of World Health Organization (WHO) in 1999, type 2 diabetes mellitus was diagnosed clinically. The age ranged from 18 to 70 years (including 18 and 70 years). There was no limit to the duration of diabetes mellitus and gender.
• • (2)Basic antidiabetic therapy is not limited.
• • (3)HbA1c ≥ 7%.
• • (4)eGFR ≥60 ml/min；without contraindications to SGLT2 Inhibitors.
• • (5)Sign written consent form voluntarily.
• Exclusion Criteria:
• • (1)Other types of diabetes mellitus.
• • (2)Unstable control of blood glucose(fasting blood glucose \> 11.1 mmol/L).
• • (3)Acute complications of diabetes mellitus within 6 months.
• • (4)History of myocardial infarction or stroke within 6 months, or existing severe cardiovascular disease and risk.
• • (5)Abnormal liver function \[i.e. serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is 1.5 times higher than the upper limit of normal value\].
• • (6)Severe hypertension that defined as systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥90 mmHg with drug therapy, or hypotension (resting seat blood pressure \< 90/50 mmHg).
• • (7)psychosis, alcohol dependence or history of drug abuse, lactation women, participation in other studies three months before the trial, allergic constitution or allergic to a variety of drug and those researchers think inappropriate to the research.